Cardio-oncology & otherCase-control study
Serum Proteins Predict Treatment-Related Cardiomyopathy Among Survivors of Childhood Cancer
- Nested case-control biomarker study
- individually matched
- untargeted mass spectrometry
- independent validation sample
Authors' conclusion
A risk model was developed on the basis of the differential expression of serum proteins in subclinical cardiomyopathy, which accurately discriminated the risk for severe cardiomyopathy in an independent, matched sample.
Study context
- Population
- Childhood cancer survivors exposed to anthracyclines, SJLIFE (St. Jude Lifetime Cohort Study)validation: 23 + 23 matched
- Participants
- 75 / 75 / 23 / 23
- Comparison
- Survivors with vs without cardiomyopathy
- Subclinical cardiomyopathyn = 75
- Without cardiomyopathyn = 75reference
- Severe or symptomatic cardiomyopathyn = 23
- Cardiomyopathy-freen = 23reference
- Outcome
- Discrimination of symptomatic or severe cardiomyopathy by a serum protein/metabolite model
Main finding
As reported in the abstract
27-protein model discrimination of symptomatic or severe cardiomyopathy requiring HF medications (independent survivors)
Correctly discriminated matched survivors
19 of 23
Accuracy
82.6% (95% CI: 71.4%-93.8%)
Observational data: associations, not effects.
Further findings
Pathway enrichment
- The 27 proteins were enriched in biological processes, many linked to anthracycline-related cardiomyopathy
Original publication
Serum Proteins Predict Treatment-Related Cardiomyopathy Among Survivors of Childhood Cancer. JACC CardioOncol. Published 3 December 2024. doi:10.1016/j.jaccao.2024.10.004
Summarised from the published abstract; every number is checked against it